Bruffaerts Nicolas, Pedersen Lasse E, Vandermeulen Gaëlle, Préat Véronique, Stockhofe-Zurwieden Norbert, Huygen Kris, Romano Marta
Service Immunology, Scientific Institute for Public Health (WIV-ISP Site Ukkel), Brussels, Belgium.
Section for Immunology and Vaccinology, Technical University of Denmark, Bulowsvej Frederiksberg C, Denmark.
PLoS One. 2015 Jul 14;10(7):e0132288. doi: 10.1371/journal.pone.0132288. eCollection 2015.
The only tuberculosis vaccine currently available, bacille Calmette-Guérin (BCG) is a poor inducer of CD8(+) T cells, which are particularly important for the control of latent tuberculosis and protection against reactivation. As the induction of strong CD8(+) T cell responses is a hallmark of DNA vaccines, a combination of BCG with plasmid DNA encoding a prototype TB antigen (Ag85A) was tested. As an alternative animal model, pigs were primed with BCG mixed with empty vector or codon-optimized pAg85A by the intradermal route and boosted with plasmid delivered by intramuscular electroporation. Control pigs received unformulated BCG. The BCG-pAg85A combination stimulated robust and sustained Ag85A specific antibody, lymphoproliferative, IL-6, IL-10 and IFN-γ responses. IgG1/IgG2 antibody isotype ratio reflected the Th1 helper type biased response. T lymphocyte responses against purified protein derivative of tuberculin (PPD) were induced in all (BCG) vaccinated animals, but responses were much stronger in BCG-pAg85A vaccinated pigs. Finally, Ag85A-specific IFN-γ producing CD8(+) T cells were detected by intracellular cytokine staining and a synthetic peptide, spanning Ag85A131-150 and encompassing two regions with strong predicted SLA-10401/SLA-10801 binding affinity, was promiscuously recognized by 6/6 animals vaccinated with the BCG-pAg85A combination. Our study provides a proof of concept in a large mammalian species, for a new Th1 and CD8(+) targeting tuberculosis vaccine, based on BCG-plasmid DNA co-administration.
目前唯一可用的结核病疫苗卡介苗(BCG)对CD8(+) T细胞的诱导效果不佳,而CD8(+) T细胞对于控制潜伏性结核病和预防复发尤为重要。由于诱导强烈的CD8(+) T细胞反应是DNA疫苗的一个标志,因此测试了卡介苗与编码结核原型抗原(Ag85A)的质粒DNA的组合。作为替代动物模型,通过皮内途径用卡介苗与空载体或密码子优化的pAg85A混合对猪进行初次免疫,并用肌肉电穿孔递送的质粒进行加强免疫。对照猪接受未配制的卡介苗。卡介苗-pAg85A组合刺激了强烈且持续的Ag85A特异性抗体、淋巴细胞增殖、IL-6、IL-10和IFN-γ反应。IgG1/IgG2抗体亚型比例反映了偏向Th1辅助型的反应。在所有接种(卡介苗)的动物中均诱导了针对结核菌素纯蛋白衍生物(PPD)的T淋巴细胞反应,但在接种卡介苗-pAg85A的猪中反应要强得多。最后,通过细胞内细胞因子染色检测到产生Ag85A特异性IFN-γ的CD8(+) T细胞,并且接种卡介苗-pAg85A组合的6/6只动物均能普遍识别跨越Ag85A131-150且包含两个具有强预测SLA-10401/SLA-10801结合亲和力区域的合成肽。我们的研究为基于卡介苗-质粒DNA联合给药的新型Th1和CD8(+)靶向结核病疫苗在大型哺乳动物物种中提供了概念验证。